Business Wire

Belgian Grower Tomerel Increases Light Levels, Decreases Energy Costs Through Fluence LED Retrofit

12.5.2022 15:00:00 EEST | Business Wire | Press release

Share

Fluence, a leading global provider of energy-efficient LED lighting solutions for commercial cannabis and food production, announced today its partnership with Tomerel, a tomato grower located in Antwerp, Belgium. Together, the companies retrofitted half of Tomerel’s glasshouse from high-pressure sodium (HPS) fixtures to LEDs, resulting in a 40% increase in light levels while decreasing energy input by 5%.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220512005116/en/

Tomerel is a multi-generational family farm led by CEO and co-owner Jelle de Ryck—son of founders Els and Eric. Tomerel specializes in glasshouse-grown tomatoes, with a particular focus on cherry tomatoes on the vine. Like many growers in the region, Jelle de Ryck scaled his family’s facility using supplemental HPS fixtures. However, when Jelle sought to maximize the glasshouse’s light output and energy consumption, he turned to Fluence’s advanced LED technology.

“When we set out to identify a partner to assist with our lighting retrofit, we weren’t just looking for lights—we wanted a team that could strategize with us from installation through harvesting. Fluence provided that service and more,” said Jelle.

After installing Fluence’s VYPR 3p top light solution, what were once critical limitations to the farm’s lighting strategy became opportunities to boost yields and reduce energy costs. Traditional HPS fixtures produce excess heat and feature inflexible spectral options. Fluence LEDs, however, run cooler and use a more efficient spectrum. With exploding energy prices in the region, the lightened load on the glasshouse’s HVAC system, in combination with the LEDs’ overall more efficient energy usage, enabled Tomerel to cut its electricity usage while increasing light levels.

“Fluence’s technology drove success for us in multiple ways. The electricity efficiencies enabled us to sell 25% more energy back to the grid and also reduced our gas consumption by 5%. The plants are also thriving under LEDs. We’re seeing improved quality and production throughout the winter months, increases in stem density and improved translocation of sugars throughout the night,” Jelle added.

In close coordination with Fluence’s technical team, Tomerel implemented a PhysioSpec™ DUAL R9B spectral strategy to accommodate plant efficacy. This strategy enabled Tomerel to decrease energy input by 5% even while increasing the amount of light by 40%, ensuring stronger cultivation conditions for Tomerel’s tomato crop. As a result, Tomerel also increased its yield by more than 5% despite the facility receiving 5% less natural light over the winter season. Tomerel also saw an increase in overall fruit weight following the retrofit.

“It is fascinating to see growers like Tomerel make innovative, smart cultivation decisions regarding energy usage,” said Timo Bongartz, general manager for Europe, the Middle East and Africa for Fluence. “The Tomerel team is saving energy wherever possible and also optimizing their facility in such a way to enable them to sell energy back to the grid. And all that without sacrificing plant quality. Fluence is delighted to support Tomerel in running a future-proof glasshouse.”

With Fluence’s technology, the Tomerel team sold 25% more of the glasshouse’s electricity produced by co-generation back to the grid during peak energy prices and saved 5% of its total gas consumption.

For more information on Fluence, visit www.fluence.science.

About Fluence

Fluence Bioengineering, Inc. (Fluence) creates powerful and energy-efficient LED lighting solutions for commercial crop production and research applications. Fluence is a leading LED lighting supplier in the global cannabis market and is committed to enabling more efficient crop production with the world’s top vertical farms and greenhouse produce growers. Fluence global headquarters are in Austin, Texas, with its EMEA headquarters in Rotterdam, Netherlands. Fluence operates as a business unit within Signify’s Digital Solutions division. For more information about Fluence, visit www.fluence.science.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For Fluence
Emma Chase
pr@fluencebioengineering.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Bending Spoons S.p.A. announces filing of registration statement for proposed initial public offering8.6.2026 14:20:00 EEST | Press release

Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, announces today that it has publicly filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission (“SEC”) relating to a proposed initial public offering of its ordinary shares. The timing of the offering, number of shares to be offered, and the price range for the proposed offering have not yet been determined. Bending Spoons has applied to list its ordinary shares on the Nasdaq Global Select Market under the ticker symbol “BSP.” Goldman Sachs International, J.P. Morgan, and Allen & Company LLC are acting as joint lead book-running managers for the proposed offering. Wells Fargo Securities, BofA Securities, Jefferies, Evercore ISI, BNP Paribas, Mizuho, Societe Generale, Crédit Agricole CIB, IMI – Intesa Sanpaolo, UniCredit, and Banca Akros – Gruppo Banco BPM are acting as joint book-running managers for the proposed offering. The proposed offering is subject to market and other condit

Xsolla to Attend SuperReturn International 2026 to Advance Strategic Partnerships and Expand Its Presence in Global Private Capital8.6.2026 14:15:00 EEST | Press release

Xsolla, a global leader in video game commerce, today announced its participation in SuperReturn International 2026, taking place June 8–12 at the InterContinental Berlin. Uniting more than 6,000 senior attendees, including 2,000+ LPs and 3,000 GPs, SuperReturn International is widely recognized as the capital of private capital with the best investment opportunities globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260607269536/en/ Graphic: Xsolla The video game industry has matured into one of the largest and most resilient segments of the global entertainment economy, outpacing film and music combined, driving continuous growth through shifting market cycles. Yet the infrastructure powering how games are sold, monetized, and distributed worldwide remains under-examined by much of the institutional investment community. Xsolla's presence at SuperReturn International reflects a broader moment: the convergence of a mu

Shilpa Medicare and Gate2Brain Sign Strategic Equity Partnership to Advance First-in-Class Brain Cancer Therapy8.6.2026 13:00:00 EEST | Press release

Shilpa Biocare Pvt Ltd, a Subsidiary of Shilpa Medicare Limited (BSE/NSE: SHILPAMED) has entered a strategic equity partnership with Gate2Brain, S.L., a biotechnology company focused on CNS therapeutics. Shilpa becomes a strategic shareholder and CMC, manufacturing, and regulatory partner for G2B-002 — Gate2Brain's lead program targeting deadly pediatric brain cancers, DIPG and pGBM, both with Orphan Drug Designation from the US FDA and EMA. G2B-002 uses Gate2Brain's proprietary MiniAp4 peptide shuttle to deliver SN-38 across the blood-brain barrier, demonstrating up to 100-fold greater brain drug transport preclinically. First-in-human trials are anticipated by FY28. G2B-002 targets high-growth oncology markets — the glioblastoma market projected at USD 6.48B by 2035 (CAGR: 7.97%), pediatric brain tumors at USD 2.47B by 2031 (CAGR: 6.9%), and DIPG at USD 1.2B by 2035 (CAGR: 7.1%). Gate2Brain's MiniAp4 platform further extends potential across rare pediatric cancers and broader CNS cat

Haleon Invests in India to Deliver Better Everyday Health to Rural Communities8.6.2026 12:11:00 EEST | Press release

Haleon, a consumer company that is solely focused on better everyday health, today announces plans to expand its business in India, one of its fastest-growing markets and key to Haleon delivering its strategy and ambitions to reach one billion more consumers by 2030. Haleon will invest approximately £175 million2 in building a new oral health manufacturing site in Madhya Pradesh, central India and accelerate distribution efforts in rural India to meet rising demand. The new site will also support supply for wider Asia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608753094/en/ Haleon Health Ambassador on motorbike, equipped with testing kits, samples and diagnostic tools Building capacity to meet rising demand The new site, which is well-positioned in the middle of the country and close to some of India’s most renowned technical colleges, marks an important step in the delivery of Haleon’s Win as One strategy. Win as On

Diabetology’s Breakthrough Clinical Data From Oraglutide™ Oral GLP-18.6.2026 11:56:00 EEST | Press release

Diabetology Limited (Jersey) poster presentation (https://diabetology.co.uk/ada-poster) 1724-P at the ADA 86th Scientific Session, New Orleans, reporting first human data from Oraglutide™ — small capsule intestinally-released oral semaglutide, formulated using the proprietary Axcess™ delivery technology. KEY HIGHLIGHTS 6-day glucose control: A single 4 mg oral dose of Oraglutide™ produced a sustained fall in glucose. Measuring 14% at Day 6 (p=.046), the longest duration presented from a single oral GLP-1 dose in a human IVGTT study. 28% increase in insulin secretion: Relative to placebo, insulin percent AUC increased by 12% day 0, (p=0.02) & 28% Day 1 (p = 0.025). Novel intestinal depot effect: Blood levels of semaglutide were higher on Day 1 than dosing on Day 0, consistent with lipid associated depot effect in the intestinal wall, a fundamentally new pharmacological finding. No nausea or side effects observed: No adverse events observed across the 8-subject cohort over one week, cons

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye